The effect of obesity on rectal dosimetry after permanent prostate brachytherapy

Brachytherapy

Volumn 8, Issue 2, 2009, Pages 218-222

  Patil, Nikhilesh ^a   Crook, Juanita ^a   Saibishkumar, Elantholi P ^a   Aneja, Manipdip ^a   Borg, Jette ^a   Pond, Greg ^a   Ma, Clement ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Body mass index; Permanent seed prostate brachytherapy; Prostate cancer; Rectal dose

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RECTUM DISEASE;

BODY MASS INDEX; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OBESITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349140634     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.12.001     Document Type: Article

References (22)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Rockhill J., Wallner K., Hoffman C., et al. Prostate brachytherapy in obese patients. Brachytherapy 1 (2002) 54-60
3. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 65 (2005) 95-100
4. Mitsuyama H., Wallner K.E., and Merrick G.S. Treatment of prostate cancer in obese patients. Oncology (Williston Park) 20 (2006) 1191-1197 discussion 1198, 1206, 1208
5. Halabi S., Ou S.S., Vogelzang N.J., et al. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 110 (2007) 1478-1484
6. Skolarus T.A., Wolin K.Y., and Grubb III R.L. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 4 (2007) 605-614
7. Davies B.J., Walsh T.J., Ross P.L., et al. Effect of BMI on primary treatment of prostate cancer. Urology 72 (2008) 406-411
8. Efstathiou J.A., Skowronski R.Y., Coen J.J., et al. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 71 (2008) 1302-1308
9. Pasulka P.S., Bistrian B.R., Benotti P.N., et al. The risks of surgery in obese patients. Ann Intern Med 104 (1986) 540-546
10. Luchka K., and Shalev S. Pelvic irradiation of the obese patient: A treatment strategy involving megavoltage simulation and intratreatment setup corrections. Med Phys 23 (1996) 1897-1902
11. Crook J.M., Raymond Y., Salhani D., et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37 (1995) 35-42
12. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
13. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 179 (2008) S20-S24
14. Merrick G.S., Butler W.M., Wallner K., et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 60 (2002) 104-108
15. Crook J., McLean M., Yeung I., et al. MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy. Brachytherapy 3 (2004) 55-60
16. Crook J., Milosevic M., Catton P., et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy 1 (2002) 66-73
17. Crook J.M., Potters L., Stock R.G., et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 4 (2005) 186-194
18. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
19. Crook J., Esche B., and Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspective. Urology 47 (1996) 387-394
20. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
21. Nag S., Ellis R.J., Merrick G.S., et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 54 (2002) 462-470
22. Sylvester J., Merrick G.S., Grimm P., et al. Influence of Pro-Qura feedback on rectal dosimetry following permanent prostate brachytherapy. Brachytherapy 7 (2008) 121-122